Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for ...

The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades. The drug, suzetrigine, is a 50-milligram prescription pill ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.

If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. For the first time in over two decades, the U.S. Food and Drug Administration (FDA) has ...

The endTB trial is one of four recent randomized controlled trials testing new, shorter, and less toxic treatment regimens ...

Prescribing information for the new meloxicam-rizatriptan product comes with a long list of precautions and contraindications. The drug's label includes a boxed warning that spells out the ...